According to a recent LinkedIn post from Neurolief, the company has closed a $6 million milestone‑based investment from BrainsWay Ltd. The post indicates that the funding is intended to support efforts to expand access to treatment options for adults with Major Depressive Disorder who have not responded adequately to antidepressant medications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights Neurolief’s Proliv™Rx therapy, described as a clinically supervised, home‑delivered brain neuromodulation solution aimed at addressing current treatment and access limitations. For investors, the milestone‑based structure and strategic alignment with BrainsWay suggest a focus on execution and clinical validation in the neurotech and digital mental‑health markets.
The emphasis on the economic and emotional burden of depression in the post underscores a large addressable market if Neurolief can demonstrate efficacy, reimbursement viability, and scalable home delivery. This development may strengthen the company’s positioning within neuromodulation and medtech, potentially supporting future fundraising, partnership opportunities, or market expansion if milestones are successfully achieved.